©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Mar 27, 2023; 15(3): 386-392
Published online Mar 27, 2023. doi: 10.4254/wjh.v15.i3.386
Published online Mar 27, 2023. doi: 10.4254/wjh.v15.i3.386
Emerging role of engineered exosomes in nonalcoholic fatty liver disease
Jian Ding, Chen Xu, Ming Xu, Department of Hepatobiliary Surgery, Xi-Jing Hospital, The Fourth Military Medical University, Xi'an 710032, Shaanxi Province, China
Xiao-Yue He, The Affiliated Hospital of Jining Medical University, Jining Medical University, Jining 272067, Shandong Province, China
Wei-Na Li, School of Basic Medicine, The Fourth Military Medical University, Xi'an 710032, Shaanxi Province, China
Fei He, Department of Hepatobiliary Surgery, Xi-Jing Hospital, Xi'an 710032, Shaanxi Province, China
Author contributions: Ding J contributed to writing the original draft; Xu C contributed to picture making; Xu M, He XY, and Li WN contributed to data collection; He F contributed to designed the review and revised the final version.
Supported by National Natural Science Foundation of China , No. 81970535 .
Conflict-of-interest statement: All the authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Corresponding author: Fei He, PhD, Research Associate, Department of Hepatobiliary Surgery, Xi-Jing Hospital, No. 127 Changle West Road, Xi'an 710032, Shaanxi Province, China. hefei_hefei@163.com
Received: December 26, 2022
Peer-review started: December 26, 2022
First decision: February 1, 2023
Revised: February 20, 2023
Accepted: March 15, 2023
Article in press: March 15, 2023
Published online: March 27, 2023
Processing time: 86 Days and 5.8 Hours
Peer-review started: December 26, 2022
First decision: February 1, 2023
Revised: February 20, 2023
Accepted: March 15, 2023
Article in press: March 15, 2023
Published online: March 27, 2023
Processing time: 86 Days and 5.8 Hours
Core Tip
Core Tip: Nonalcoholic fatty liver disease (NAFLD) is the fastest growing chronic disease in the world. As the disease progresses, NAFLD can lead to liver fibrosis, cirrhosis and even liver cancer. However, a well-established treatment for NAFLD has yet to be identified. Exosomes are small extracellular vesicles secreted by cells. Owing to their high delivery efficiency and biocompatibility, exosomes are expected to become a new means of drug delivery and precise treatment for a variety of diseases, including NAFLD.